Jade Biosciences (JBIO) Operating Leases (2021 - 2026)

Jade Biosciences (JBIO) has 6 years of Operating Leases data on file, last reported at $679000.0 in Q1 2026.

• Quarterly Operating Leases changed N/A year-over-year to $679000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $679000.0 (changed N/A YoY) and the FY2025 annual result came in at $724000.0, changed N/A from the prior year.
• Operating Leases fell to $679000.0 in Q1 2026, from $724000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $1.2 million in Q2 2022 to a low of $81000.0 in Q3 2024.
• A 5-year average of $562200.0 and a median of $591000.0 in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2024 — Operating Leases slumped 77.37% — and 2025, when it jumped 764.2%.
• Tracing JBIO's Operating Leases over 5 years: stood at $705000.0 in 2022, then tumbled by 63.83% to $255000.0 in 2023, then plunged by 68.24% to $81000.0 in 2024, then soared by 793.83% to $724000.0 in 2025, then declined by 6.22% to $679000.0 in 2026.
• The last three Operating Leases figures came in at $679000.0 (Q1 2026), $724000.0 (Q4 2025), and $700000.0 (Q3 2025), per Business Quant data.